利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.025 秒)

    Method of treating tumors using O-substituted fumagillol derivatives
    1.
    发明授权
    Method of treating tumors using O-substituted fumagillol derivatives 失效
    使用O-取代的烟曲霉醇衍生物治疗肿瘤的方法

    公开(公告)号：US6017954A

    公开(公告)日：2000-01-25

    申请号：US940123

    申请日：1992-09-03

    申请人： Moses J. Folkman ,  Donald Ingber ,  Takeshi Fujita

    发明人： Moses J. Folkman ,  Donald Ingber ,  Takeshi Fujita

    IPC分类号： A61K31/335 ,  A61K31/336 ,  C07D303/22 ,  C07D405/14 ,  C07D407/14 ,  C07D417/14 ,  C07D521/00 ,  A01N43/20

    CPC分类号： C07D303/22 ,  A61K31/335 ,  A61K31/336 ,  C07D231/12 ,  C07D233/56 ,  C07D249/08 ,  C07D405/14 ,  C07D407/14 ,  C07D417/14

    摘要： This invention relates to methods of using O-substituted fumagillol derivatives or salts thereof preferably, O-(N-chloroacetylcarbamoyl) fumagillol, O-(N-chloroacetylcarbamoyl)dihydrofumagillol or O-(N-chloracetylcarbamoyl)-6'b-hydroxyfumagillol, which have angiogenesis inhibitory activity, in the treatment and prevention of various diseases caused or advanced by abnormally hyperactive angiogenesis, especially various inflammatory diseases (rheumatism, psoriasis, etc.), diabetic retinopathy and cancer and other angiogenesis-dependent tumors, especially Kaposi's sarcoma, breast cancer, colon cancer.

    摘要翻译： 本发明涉及使用O-取代的烟曲霉醇衍生物或其盐优选O-（N-氯乙酰基氨基甲酰基）烟曲霉醇，O-（N-氯乙酰基氨基甲酰基）二氢烟曲霉素或O-（N-氯乙酰基氨基甲酰基）-6'-羟基烟曲霉素的方法，其中 具有血管生成抑制活性，用于治疗和预防由异常血液生成异常引起或促进的各种疾病，特别是各种炎性疾病（风湿病，牛皮癣等），糖尿病性视网膜病变和癌症以及其它血管生成依赖性肿瘤，特别是卡波西肉瘤，乳腺癌 癌症，结肠癌。

    Porous biodegradable polymeric materials for cell transplantation
    6.
    发明申请
    Porous biodegradable polymeric materials for cell transplantation 失效

    公开(公告)号：US20060141000A1

    公开(公告)日：2006-06-29

    申请号：US10775768

    申请日：2004-02-10

    申请人： Antonios Mikos ,  Donald Ingber ,  Joseph Vacanti ,  Robert Langer

    发明人： Antonios Mikos ,  Donald Ingber ,  Joseph Vacanti ,  Robert Langer

    IPC分类号： A61K35/12

    CPC分类号： G02B27/0031 ,  A61L27/18 ,  A61L27/56 ,  A61L2400/06 ,  G03F7/40 ,  H01L21/0273 ,  H01L21/32139 ,  C08L67/04

    摘要： Polymeric materials are used to make a pliable, non-toxic, injectable porous template for vascular ingrowth. The pore size, usually between approximately 100 and 300 microns, allows vascular and connective tissue ingrowth throughout approximately 10 to 90% of the matrix following implantation, and the injection of cells uniformly throughout the implanted matrix without damage to the cells or patient. The introduced cells attach to the connective tissue within the matrix and are fed by the blood vessels. The preferred material for forming the matrix or support structure is a biocompatible synthetic polymer which degrades in a controlled manner by hydrolysis into harmless metabolites, for example, polyglycolic acid, polylactic acid, polyorthoester, polyanhydride, or copolymers thereof. The rate of tissue ingrowth increases as the porosity and/or the pore size of the implanted devices increases. The time required for the tissue to fill the device depends on the polymer crystallinity and is less for amorphous polymers versus semicrystalline polymers. The vascularity of the advancing tissue is consistent with time and independent of the biomaterial composition and morphology.